Interleukin-12 Inhibits Angiogenesis Induced by Human Tumor Cell Lines in Vivo

Journal of Investigative Dermatology

Volumn 106, Issue 5, 1996, Pages 1114-1118

  Majewski, Slawomir ^a   Marczak, Maria ^a   Szmurlo, Andrzej ^a   Jablonska, Stefania ^a   Bollag, Werner ^b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Inhibition of angiogenesis; Interleukin 12; Tumor angiogenesis

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; PREVENTION; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RATS; TUMOR CELLS, CULTURED;

EID: 0029930406     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/1523-1747.ep12340161     Document Type: Article

References (35)

1. Bouck N: Tumor angiogenesis: the role of oncogenes and tumor suppressor genes. Cancer Cells 2:179-185, 1990
2. Brunda MJ: Interleukin-12. J Leukoc Biol 55:280-288, 1994
3. Brunda MJ, Gately MK: Antitumor activity of interleukin-12. Clin Immunol Immunopathol 71:253-255, 1994
4. Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garrota G, Gately MK: Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J Immunother 17:71-77, 1995
5. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178:1223-1230, 1993
6. Denekamp J: Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66:181-196, 1993
7. Dvorak HF, Sioussat TM, Brown LF: Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 174:1275-1278, 1991
8. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186, 1971
9. Folkman J: What is the evidence that tumors are angiogenesis- dependent? J Natl Cancer Inst 82:4-6, 1990
10. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1:27-31, 1995
11. Gately MK, Gubler U, Brunda MJ, Nadeau RR, Anderson TD, Lipman JM, Sarmiento U: Interleukin-12: a cytokine with therapeutic potential in oncology and infectious diseases. Ther Immunol 1:187-196, 1994a
12. Gately MK, Warrier RR, Honasoge S: Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces IFN-γ in vivo. Int Immunol 6:157-167, 1994b
13. Gottesman MM: Report of a meeting: molecular basis of cancer therapy. J Natl Cancer Inst 86:1277-1285, 1994
14. Gubler U, Chua AO, Schoenhaut DS, Dwyer CM, McComas W, Motyka R, Nabavi N, Wolitzky AG, Quinn PM, Familletti PC, Gately MK: Coexpression of two distinct genes is required to generate secreted, bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 88:4143-4147, 1991
15. Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF, Brown LF: Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Canter Inst 87:1237-1245, 1995
16. Ingber D, Folkman J: Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest 59:44-51, 1988
17. Kaminski MJ, Majewski S, Jablonska S, Pawinska M: Lowered angiogenic capability of peripheral blood lymphocytes in progressive systemic sclerosis (scleroderma). J Inverst Dermatol 82:239-243, 1984
18. Karp JE, Broder S. Molecular foundations of cancer: new targets for intervention. Nature Med 1:309-319, 1995
19. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327-336, 1991
20. Maione TE, Sharpe RJ: Development of angiogenesis inhibitors for clinical applications. Trends Pharmacol Sci 11:457-461, 1990
21. Majewski S, Kaminski MJ, Szmurlo A, Kaminska G, Malejczyk J: Inhibition of tumor-induced angiogenesis in mice by systemically administered protamine sulphate. Int J Cancer 33:831-833, 1984
22. 3 and their combination inhibit angiogenesis induced by non-HPV-harboring tumor cell lines. RAR mediates the antiangiogenic effect of retinoids. Cancer Lett 89:117-124, 1995
23. Majewski S, Polakowski I, Marczak M, Jablonska S: The effects of retinoids on lymphocyte- and transformed cell line-induced angiogenesis. Clin Exp Dermatol 2:317-318, 1986
24. 3 and their combination. Cancer Lett 75:35-39, 1993
25. Majewski S, Szmurlo A, Marczak M, Jablonska S, Bollag W: Synergistic effect of retinoids and interferon-α on tumor-induced angiogenesis: anti-angiogenic effect on HPV-harboring tumor cell lines. Int J Cancer 57:81-85, 1994
26. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ, Lotze MT: Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 153:1697-1706, 1994
27. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328, 1994
28. Rastinejad F, Polverini PJ, Bouck NP: Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 56:345-355, 1989
29. Sato N, Nariuchi H, Tsuruoka N, Nishihara T, Beitz JG, Calabresi P, Frackelton R: Actions of TNFα and IFNγ on angiogenesis in vivo. J Invest Dermatol 95:85s-89s, 1990
30. Schneider-Maunoury S, Pehau-Arnaudent G, Breitburd F, Orth G: Expression of the human papillomavirus type 16 genuine in SK-v cells, a line derived from a vulvar intraepithelial neoplasia. J Gen Virol 71:809-817, 1990
31. Sidky YA, Anerbach R: Lymphocyte-induced angiogenesis: a quantitative and sensitive assay of the graft-versus-host reaction. J Exp Med 141:1084-1100, 1975
32. Sidky YA, Borden EC: Inhibition of angingenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 47:5155-5161, 1987
33. Van Meir EG: Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nature Genet 8:171-176, 1994
34. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato KJ, Folkman J: Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581-586, 1995
35. Wolf SF, Temple PA, Kobayashi M, Young D, Ding M, Lowe L, Dzialo T, Fitz L, Ferenz D, Hewick RM: Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biological effects on T and natural killer cells. J Immunol 146:31174-3079, 1991